- Home
- SABR vs KROS Comparison
SABR vs KROS Comparison
Compare SABR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- KROS
- Stock Information
- Founded
- SABR 2006
- KROS 2015
- Country
- SABR United States
- KROS United States
- Employees
- SABR N/A
- KROS N/A
- Industry
- SABR Computer Software: Programming Data Processing
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- KROS Health Care
- Exchange
- SABR Nasdaq
- KROS Nasdaq
- Market Cap
- SABR 706.2M
- KROS 565.0M
- IPO Year
- SABR 2014
- KROS 2020
- Fundamental
- Price
- SABR $1.90
- KROS $15.40
- Analyst Decision
- SABR Buy
- KROS Buy
- Analyst Count
- SABR 5
- KROS 14
- Target Price
- SABR $4.12
- KROS $20.56
- AVG Volume (30 Days)
- SABR 4.4M
- KROS 919.9K
- Earning Date
- SABR 11-05-2025
- KROS 11-05-2025
- Dividend Yield
- SABR N/A
- KROS N/A
- EPS Growth
- SABR N/A
- KROS N/A
- EPS
- SABR N/A
- KROS 0.47
- Revenue
- SABR $3,010,157,000.00
- KROS $232,844,000.00
- Revenue This Year
- SABR N/A
- KROS $6,657.47
- Revenue Next Year
- SABR $3.91
- KROS N/A
- P/E Ratio
- SABR N/A
- KROS $33.11
- Revenue Growth
- SABR 6.13
- KROS 85820.30
- 52 Week Low
- SABR $1.69
- KROS $9.12
- 52 Week High
- SABR $4.63
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- SABR 54.80
- KROS 50.90
- Support Level
- SABR $1.76
- KROS $13.60
- Resistance Level
- SABR $1.86
- KROS $15.46
- Average True Range (ATR)
- SABR 0.06
- KROS 0.75
- MACD
- SABR 0.02
- KROS -0.11
- Stochastic Oscillator
- SABR 90.63
- KROS 60.61
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.